Page last updated: 2024-09-05

lenalidomide and Carcinoma, Squamous Cell of Head and Neck

lenalidomide has been researched along with Carcinoma, Squamous Cell of Head and Neck in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cohen, EE; de Souza, J; Goloubeva, O; Jain, A; Kronsberg, S; Nagilla, M; Saloura, V; Seiwert, T; Silpino, L; Taylor, RJ; Villaflor, V; Vokes, E; Wong, S	1

Trials

1 trial(s) available for lenalidomide and Carcinoma, Squamous Cell of Head and Neck

Article	Year
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer immunology research, 2015, Volume: 3, Issue:5 Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Receptors, IgG; Squamous Cell Carcinoma of Head and Neck; Thalidomide; Treatment Outcome	2015

Article

Year

Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.

Cancer immunology research, 2015, Volume: 3, Issue:5

Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Receptors, IgG; Squamous Cell Carcinoma of Head and Neck; Thalidomide; Treatment Outcome

2015